A p38 MAPK-ROS axis fuels proliferation stress and DNA damage during CRISPR-Cas9 gene editing in hematopoietic stem and progenitor cells

在造血干细胞和祖细胞中,p38 MAPK-ROS轴在CRISPR-Cas9基因编辑过程中促进增殖应激和DNA损伤。

阅读:6
作者:Lucrezia Della Volpe ,Federico Midena ,Roberta Vacca ,Teresa Tavella ,Laura Alessandrini ,Giacomo Farina ,Chiara Brandas ,Elena Lo Furno ,Kety Giannetti ,Edoardo Carsana ,Matteo M Naldini ,Matteo Barcella ,Samuele Ferrari ,Stefano Beretta ,Antonella Santoro ,Simona Porcellini ,Angelica Varesi ,Diego Gilioli ,Anastasia Conti ,Ivan Merelli ,Bernhard Gentner ,Anna Villa ,Luigi Naldini ,Raffaella Di Micco

Abstract

Ex vivo activation is a prerequisite to reaching adequate levels of gene editing by homology-directed repair (HDR) for hematopoietic stem and progenitor cell (HSPC)-based clinical applications. Here, we show that shortening culture time mitigates the p53-mediated DNA damage response to CRISPR-Cas9-induced DNA double-strand breaks, enhancing the reconstitution capacity of edited HSPCs. However, this results in lower HDR efficiency, rendering ex vivo culture necessary yet detrimental. Mechanistically, ex vivo activation triggers a multi-step process initiated by p38 mitogen-activated protein kinase (MAPK) phosphorylation, which generates mitogenic reactive oxygen species (ROS), promoting fast cell-cycle progression and subsequent proliferation-induced DNA damage. Thus, p38 inhibition before gene editing delays G1/S transition and expands transcriptionally defined HSCs, ultimately endowing edited cells with superior multi-lineage differentiation, persistence throughout serial transplantation, enhanced polyclonal repertoire, and better-preserved genome integrity. Our data identify proliferative stress as a driver of HSPC dysfunction with fundamental implications for designing more effective and safer gene correction strategies for clinical applications.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。